Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-03-03 10:06 am Sale | 13D | CINCOR PHARMA INC CINC | Sofinnova Capital IX | 0 0% | -4,220,979 (Position Closed) | View |
| 2023-03-01 1:38 pm Sale | 13D | CINCOR PHARMA INC CINC | Sofinnova Venture Partners X L.P. | 0 0% | -6,109,360 (Position Closed) | View |
| 2023-02-28 4:30 pm Sale | 13D | CINCOR PHARMA INC CINC | 5AM Ventures VI L.P. | 0 0% | -4,937,646 (Position Closed) | View |
| 2023-02-28 4:16 pm Sale | 13D | CINCOR PHARMA INC CINC | GENERAL ATLANTIC L.P. | 0 0% | -4,209,470 (Position Closed) | View |
| 2023-02-14 2:30 pm Purchase | 13G | CINCOR PHARMA INC CINC | PERCEPTIVE ADVISORS LLC | 2,576,325 5.9% | 2,576,325 (New Position) | View |
| 2023-02-13 1:33 pm Purchase | 13D | CINCOR PHARMA INC CINC | Sofinnova Capital IX | 4,220,979 9.6% | 4,220,979 (New Position) | View |
| 2023-02-09 08:33 am Purchase | 13G | CINCOR PHARMA INC CINC | ADAGE CAPITAL PARTNERS GP L.L.C. | 2,993,182 6.84% | 852,636 (+39.83%) | View |
| 2023-01-18 4:00 pm Purchase | 13D | CINCOR PHARMA INC CINC | 5AM Ventures VI L.P. | 4,937,646 11.3% | 600,000 (+13.83%) | View |
| 2023-01-11 3:01 pm Purchase | 13D | CINCOR PHARMA INC CINC | GENERAL ATLANTIC L.P. | 4,209,470 9.6% | 83,000 (+2.01%) | View |
| 2022-09-26 4:18 pm Sale | 13G | CINCOR PHARMA INC CINC | venBio Global Strategic Fund III L.P. | 1,862,256 4.9% | -118,450 (-5.98%) | View |
| 2022-08-19 5:38 pm Purchase | 13D | CINCOR PHARMA INC CINC | Sofinnova Venture Partners X L.P. | 6,109,360 14.3% | 535,411 (+9.61%) | View |
| 2022-01-21 4:47 pm Purchase | 13G | CINCOR PHARMA INC CINC | ADAGE CAPITAL PARTNERS GP L.L.C. | 2,140,546 5.86% | 2,140,546 (New Position) | View |
| 2022-01-21 4:15 pm Purchase | 13G | CINCOR PHARMA INC CINC | 5AM Ventures VI L.P. | 4,337,646 11.9% | 4,337,646 (New Position) | View |
| 2022-01-21 3:19 pm Purchase | 13D | CINCOR PHARMA INC CINC | Sofinnova Venture Partners X L.P. | 5,573,949 15.3% | 5,573,949 (New Position) | View |
| 2022-01-21 1:07 pm Purchase | 13D | CINCOR PHARMA INC CINC | GENERAL ATLANTIC L.P. | 4,126,470 11.3% | 4,126,470 (New Position) | View |
| 2022-01-11 4:46 pm Purchase | 13G | CINCOR PHARMA INC CINC | venBio Global Strategic Fund III L.P. | 1,980,706 5.6% | 1,980,706 (New Position) | View |
| 2022-01-11 4:05 pm Purchase | 13G | CINCOR PHARMA INC CINC | CinRx Pharma LLC | 3,630,102 7.8% | 3,630,102 (New Position) | View |